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E d i t o r i a l s
T h e ne w e ngl a nd jou r na l o f m e dicine n engl j med 378;4 nejm. In this issue of the Journal, Honig et al. 2 report the results of the EXPEDITION3 trial of solanezu mab, a humanized monoclonal antibody that has been designed to clear soluble Aβ from the brain. This trial was a followup to two earlier trials of solanezumab, 3 in which secondary analyses showed a modest effect in slowing cognitive de cline. Unfortunately, the EXPEDITION3 trial did not replicate this earlier finding and instead be comes another disappointment for amyloid im munotherapy. Although several trials of other immunotherapies are ongoing, this outcome raises several broader issues.
The EXPEDITION3 trial included only patients with mild cases of Alzheimer's disease who had some evidence of amyloid disease, as determined either by means of florbetapir (an 18 fluorine labeled reagent that binds to Aβ) positron emission tomography or by means of cerebro spinal fluid measurements of Aβ142. Although this effort does not differ substantially from others that have sought to intervene at an early stage of disease, which might be more amenable to treatment, it brings up the question, "How early is early enough?" Researchers have known for some time that the mouse models that we rely on to provide preclinical data are much closer to humans with prodromal Alzheimer's disease than to persons who have the earliest symptomatic stages of the disease. 4 A reasonable argument has been made that antiamyloid thera pies may yet work as a primary preventive strat egy. 5 For example, persons who have a strong family history of Alzheimer's disease or who have a dominantly inherited amyloid mutation are motivated participants in clinical trials for the prevention of Alzheimer's disease. Although two ongoing trials -DIANTU (Dominantly Inherited Alzheimer Network Trial, involving persons with dominantly inherited mutations; ClinicalTrials.gov number, NCT01760005) and A4 (AntiAmyloid Treatment in Asymptomatic Alzheimer's Trial, involving persons at risk for Alzheimer's disease; NCT02008357) -will par tially address the question of amyloid removal in disease prevention, we are still several years from knowing their results.
The trial conducted by Honig et al. could point to an alternative possibility, one that is potentially more promising (or at least intrigu ing). The authors point out that solanezumab was highly effective at targeting soluble Aβ. Al though it is possible that the magnitude of re duction in soluble Aβ was simply insufficient to create a measurable clinical benefit, recent re sults from an early trial of aducanumab could indicate that the ability of an antiamyloid therapy to clear insoluble Aβ is an important factor in the success of treatment. 6 If clearing previously deposited amyloid from the brain is more impor tant than preventing its production, this could also at least partially explain the lack of success with other strategies such as betasecretase in hibitors that have, after initial promise, 7 proved disappointing. 8 It is also possible that some other characteristic of aducanumab, such as its relatively higher penetration in the brain, as com pared with solanezumab, explains the difference. A final determination rests on the outcome of ongoing studies of aducanumab (ENGAGE [NCT02477800] and EMERGE [NCT02484547]), which expand the scope to an international trial (at different sites).
Although it may not quite be time to give up on Aβ immunotherapy for treating Alzheimer's disease, it would be foolish to ignore the contin ued failures of antiamyloid approaches. In spite of the mountain of evidence supporting the primacy of Aβ in Alzheimer's disease, many re searchers are coming to the realization that our preclinical models of the disease may be miss ing the mark. Even if there is some future suc cess in a primary prevention trial, there is still little headway being made in improving the treatment of Alzheimer's disease. There is some hope that a combination of therapeutic approach es might help, since there is evidence that the different pathologic aspects of Alzheimer's dis ease are interactive. 9 Whether a multifaceted strategy or something entirely unforeseen is the answer, the field is clearly in need of innovative ideas. We may very well be nearing the end of the amyloidhypothesis rope, at which point one or two more failures will cause us to loosen our grip and let go.
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